The susceptibility of patients with type-2 diabetes to hepatitis C virus infection during long-term haemodialysis

Swiss Medical Weekly

Volumn 133, Issue 45-46, 2003, Pages 611-618

  Saxena, Anil K ^a   Panhotra, B R ^a  

^a KING FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Haemodialysis; HCV infection; Prevalence; Sero conversion; Type 2 diabetics

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; ENVIRONMENTAL FACTOR; FEMALE; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RETROSPECTIVE STUDY; SEROCONVERSION;

EID: 0345827848     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hassan AA, Khalil RY. Prevalence of three blood borne viruses (HBV, HCV, HIV-1) among hemodialysis patients in Cairo. Saudi Kidney Dis Transplant Bull 1993;4:72.
2. Huraib S, Al Rasheed R, Aldrees A, Jeffery M. High prevalence and risk factors for hepatitis C in Saudi Arabia: A need for strategies in dialysis practice. Nephrol Dial Transplant 1995;10:470-4.
3. Legendre CH, Garrigue V, Le Bihan C, Mamzer-Bruneel MF, Chaix ML, Landais P, et al. Harmful long-term impact of hepatitis C infection in kidney transplant recipients. Transplantation 1998;65:667-70.
4. MC Laughlin KJ, Cameron SO, Good T. Nosocomial transmission of hepatitis C within a British dialysis center. Nephrol Dial Transplant 1997;12:304-9.
5. De Lamballerie X, Olmer M, Bouchouareb D, Zandotti C, De Micco P. Nosocomial transmission of hepatitis C virus in hemodialysis patients. J Med Virol 1996;49:296-302.
6. Saxena AK, Panhotra BR, Sundaram DS. The role, the type of vascular access plays in the transmission of hepatitis C virus in a high prevalence hemodialysis unit. J Vasc Access 2002;3(4):158-63.
7. Rodriguez J, Claries M, Vela E, and Renal Registry Committee. Diabetic patients on renal replacement therapy: analysis of Catalan registry data. Nephrol Dial Transplant 1997;12:2501-9.
8. Miles AM, Friedman EA. Dialytic therapy for diabetic patients with terminal renal failure. Curr Opin Nephrol Hypertens 1993;6:869-75.
9. Alain GB, Sharon S, Frederick LB. Diabetes and risk of infection-related mortality in the U.S. Diabetes Care 2001;24:1044-9.
10. Sangiorgio L, Attardo T, Gangèmi R, Rubino C, Barone M, Lunetta M. Increased frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res Clin Pract 2000;48:147-51.
11. CDC Update: Recommendations to prevent hepatitis B virus transmission United States MMWR 1995;44:574-175.
12. Centers for Disease Control and Prevention (CDC): Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001;50:1-43.
13. Saxena AK, Panhotra BR, Naguib M, Aboras MN, Sundaram DS, Venkateshappa CK, Uzzaman W. Prevalence of hepatitis C antibodies among hemodialysis patients in Al-Hasa region of Saudi Arabia. Saudi J Kidney Dis Transplant 2001;12:562-5.
14. Shaheen FAM, Huraib SO, Al Rasheed R. Prevalence of hepatitis C antibodies among hemodialysis patients of western province of Saudi Arabia. Saudi J Kidney Dis Transplant 1995;6:136-9.
15. Tokars J, Miller ER, Alter MJ, Arduino M. National surveillance of hemodialysis associated diseases in the United States, 1995. ASAIO J 1998;44:98.
16. Van der Poel CL. Hepatitis C and blood transfusion: past and present risks. J Hepatol 1999;31:101-6.
17. Bahrani A, Panhotra BR. Prevalence of hepatitis B surface antigen and anti-HCV antibodies in blood donors of Al-Hasa region of Saudi Arabia. Ann Saudi Med 2001;21:234-5.
18. Stuyver L, Claeys H, Wyseur A. Hepatitis C virus in hemodialysis unit: molecular evidence for nosocomial transmission. Kidney Int 1996;49:889-95.
19. Dentico P, Boungiorno R, Volpe A. Prevalence and Incidence of Hepatitis C virus in Hemodialysis patients: Study of risk factors. Clin Nephrol 1992;38:49-52.
20. Alfurayah O, Sabeel A, Al Ahdal MN, Almeshari K, Hamid M, Dela Cruz DM. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol 2000;20:103-6.
21. Valtuille R, Fernandez JL, Berridi J, Moretto H, del Pina N, Rendo P, Lef L. Evidence of hepatitis C virus passage across dialysis membrane. Nephron 1998;80:194-5.
22. Yuasa T, Ishikawa G, Manabe, Sekiguchi S, Takeuchi K, Miyamura T. The particle size of hepatitis C virus estimated by filtration through microporous regenerated cellulose fibre. J Gen Virol 1991;72:2021-4.
23. Okuda K, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusion among hemodialysis patients. J Hepatol 1995;23:28-31.
24. Gilles P, Moretti M, Soffritti S. Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients. Int J Artif Organs 1990;13:737-41.
25. Krause G, Trepka MJ, Whisenhunt RS, Kartz D, Nainan O, Wiersma ST, Hopkins RS. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect Control Hosp Epidemiol 2003;34:122-7.
26. Giammaria U, De Moe F, Acetelli S, et al. HCV infection in hemodialyzed patients: Incidence and correlation and dialytic age. Nephron 1992;61:335-6.
27. Hardy NM, Sandroni S, Danielson S, Wilsom WJ. Antibody to Hepatitis C Virus increases with time on hemodialysis. Clin Nephrol 1992;38:44-8.
28. Jadoul M, Cornu C, Van Ypersele De Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: A prospective study. Kidney Int 1993;44:1322-6.
29. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996;19:998-1000.
30. Soma J, Saito T, Taguma Y, Chiba S, Sato H, Sugimura K, et al. High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 2000;11:690-9.
31. Mac Mohan MM, Bistrian BR. Host defences and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am 1995;9:1-9.
32. Hirokawa K, Utsuyama M, Kasai M, et al. Aging and immunity. Acta Pathol Jpn 1992;42:537-48.
33. Ozyilkan E, Erbas T, Simsek H, et al. Increased prevalence of hepatitis c virus in patients with diabetes mellitus. J Intern Med 1994;235:283-4.
34. Latscha BD, Jungers P, Witko-Sarsat V. Immune system dysregulation in uremia: role of oxidative stress. Blood Purif 2002;20:481-4.
35. Pecoits-Filho R, Landholm B, Stenvinkel P. The malnutrition, inflammation and atherosclerosis (MIA) syndrome. Nephrol Dial Transplant 2002;17:28-31.
36. Meier P, Payer E, Blanc E, et al. Early T-cell activation correlation with expression of apoptosis markers in patients with end stage renal disease. J Am Soc Nephrol 2002;13:204-12.
37. Saxena AK, Panhotra BR. Nosocomial transmission of hepatitis C virus: Impact of strict isolation on annual seroconversion rate in hemodialysis unit. Saudi J Kidney Dis Transplant 2002;13:186-7.
38. Saxena AK, Panhotra BR, Naguib M. The impact of dedicated space, dialysis equipment and nursing staff on the transmission of hepatitis C in hemodialysis unit of the Middle East. Am J Infect Control 2003;31:26-33.